Joseph Schwartz

Stock Analyst at Leerink Partners

(0.62)
# 2126
Out of 5,319 analysts
178
Total ratings
31.67%
Success rate
-8.16%
Average return
43 Stocks
Name Action Price Target Current % Upside Ratings Updated
MAZE Maze Therapeutics
Initiates Coverage On: Outperform
28
8.41 232.94% 1 Feb 25, 2025
TVTX Travere Therapeutics
Maintains: Outperform
20 40
14.92 168.1% 6 Oct 11, 2024
APLT Applied Therapeutics
Maintains: Outperform
11 14
0.33 4142.42% 2 Sep 19, 2024
FULC Fulcrum Therapeutics
Downgrades: Market Perform
4
3.29 21.58% 3 Sep 12, 2024
ANTX AN2 Therapeutics
Upgrades: Outperform
n/a
n/a n/a 3 Jul 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
12 12
2.55 370.59% 6 Jun 24, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
6 8
2.3 247.83% 2 Jun 20, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
6
2.06 191.26% 2 Mar 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
9 2
0.12 1566.67% 5 Mar 14, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
1
1.06 -5.66% 4 Feb 9, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
10
n/a n/a 3 Dec 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
1
n/a n/a 2 Aug 18, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
6
3.5 71.43% 4 Aug 15, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
44 40
n/a n/a 3 Jun 13, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
80 115
n/a n/a 3 Jun 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Market Perform
48
47.39 1.29% 1 Mar 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
20 18
14 28.57% 5 Feb 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
30 20
12 66.67% 5 Feb 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Market Perform
33 34
28.4 19.72% 1 Feb 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
122 130
59.17 119.71% 10 Feb 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Reiterates: Outperform
160
53.79 197.45% 10 Jan 20, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
148 163
165.05 -1.24% 15 Jan 17, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
15 2
n/a n/a 6 Dec 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
15 10
0.84 1090.48% 7 Dec 7, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
40 33
1.33 2381.2% 2 Nov 10, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
17 12
7.75 54.84% 6 Nov 4, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
115 108
35.69 202.61% 6 Nov 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
52 50
72.65 -31.18% 3 Oct 27, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
64 52
n/a n/a 5 Aug 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
36 39
30.42 28.21% 1 May 26, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
6 4
1.06 277.36% 4 May 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
34 30
13.45 123.05% 2 May 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
53 50
26.66 87.55% 3 May 11, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
50 30
46.28 -35.18% 6 May 5, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
71 56
13 330.77% 1 May 3, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
124 4
n/a n/a 6 Apr 6, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
16 14
6.83 104.98% 10 Feb 24, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
112 100
n/a n/a 6 Dec 14, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Market Perform
n/a
n/a n/a 2 Dec 12, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
25
n/a n/a 1 Oct 23, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Outperform
10 12
1.14 952.63% 1 Sep 26, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Outperform
23
n/a n/a 1 Aug 28, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Outperform
n/a
n/a n/a 3 May 18, 2017